Drugs for Metabolic Disorders Market Report

China Drugs for Metabolic Disorders Industry Market Research Report 2023-2029

  • POSTDATE：Sep 29, 2023
  • PAGES：217
  • REPORT CODE：GMM1818480
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report elaborates on the current development of the Drugs for Metabolic Disorders industry thoroughly based on the international market dynamics and China's market situation.

    For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.

    Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market. 

    Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.

    By Player:

    • Beohrigher Ingelheim

    • Kythera

    • Metsubishi Tanabe Pharma

    • Astra Zeneca

    • LG Life Science

    • Takeda Pharmaceutical

    • Novartis

    • KOWA

    • Fuji yakuhin

    By Type:

    • Glycogen Metabolism Disease Drug

    • Other

    • Lipid Metabolism Disease Drug

    • Amino Acid Metabolism Drug

    By Application:

    • Hospital

    • Paramary

    By Research Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    Chapter 1 China Drugs for Metabolic Disorders Market Overview 2018-2029

    • 1.1 China Drugs for Metabolic Disorders Industry Development Overview

    • 1.2 China Drugs for Metabolic Disorders Industry Development History

    • 1.3 China Drugs for Metabolic Disorders Industry Market Size (2018-2029)

    • 1.4 China Drugs for Metabolic Disorders Market Analysis by Type from Production Side

      • 1.4.1 China Drugs for Metabolic Disorders Production Volume, Production Value and Growth Rate of Glycogen Metabolism Disease Drug (2018-2029)

      • 1.4.2 China Drugs for Metabolic Disorders Production Volume, Production Value and Growth Rate of Other (2018-2029)

      • 1.4.3 China Drugs for Metabolic Disorders Production Volume, Production Value and Growth Rate of Lipid Metabolism Disease Drug (2018-2029)

      • 1.4.4 China Drugs for Metabolic Disorders Production Volume, Production Value and Growth Rate of Amino Acid Metabolism Drug (2018-2029)

    • 1.5 China Drugs for Metabolic Disorders Market Analysis by Application from Consumption End

      • 1.5.1 China Drugs for Metabolic Disorders Sales Volume, Sales Value and Growth Rate of Hospital (2018-2029)

      • 1.5.2 China Drugs for Metabolic Disorders Sales Volume, Sales Value and Growth Rate of Paramary (2018-2029)

    • 1.6 China Drugs for Metabolic Disorders Market Analysis by Region

      • 1.6.1 North China Drugs for Metabolic Disorders Market Size and Growth Rate from 2018-2029

      • 1.6.2 Central China Drugs for Metabolic Disorders Market Size and Growth Rate from 2018-2029

      • 1.6.3 South China Drugs for Metabolic Disorders Market Size and Growth Rate from 2018-2029

      • 1.6.4 East China Drugs for Metabolic Disorders Market Size and Growth Rate from 2018-2029

      • 1.6.5 Northeast China Drugs for Metabolic Disorders Market Size and Growth Rate from 2018-2029

      • 1.6.6 Southwest China Drugs for Metabolic Disorders Market Size and Growth Rate from 2018-2029

      • 1.6.7 Northwest China Drugs for Metabolic Disorders Market Size and Growth Rate from 2018-2029

    Chapter 2 China Drugs for Metabolic Disorders Industry Development Environment

    • 2.1 Industry Development Environment Analysis

      • 2.1.1 Industry Technological Progress Analysis

      • 2.1.2 Industrial Organizational Innovation Analysis

      • 2.1.3 Changes in Social Habits

      • 2.1.4 Alterations in Government Policies

      • 2.1.5 Impact of Economic Globalization

    • 2.2 Domestic and Foreign Industry Competition Analysis

      • 2.2.1 Comparative Analysis on Drugs for Metabolic Disorders Market Status and Competition at home and abroad in 2023

      • 2.2.2 China Drugs for Metabolic Disorders Market Status and Competition Analysis in 2023

      • 2.2.3 China Drugs for Metabolic Disorders Market Concentration Analysis in 2023

    • 2.3 Problems and Countermeasures in the development of China Drugs for Metabolic Disorders Industry

      • 2.3.1 Industry Development Constraints

      • 2.3.2 Industry Development Considerations

      • 2.3.3 Suggestions on Industry Development Measures

      • 2.3.4 Development Strategies for SMEs

    • 2.4 Influence of COVID-19 Outbreak on Drugs for Metabolic Disorders Industry Development

    Chapter 3 Drugs for Metabolic DisordersIndustry Chain Analysis

    • 3.1 Drugs for Metabolic Disorders Industry Chain

    • 3.2 Drugs for Metabolic Disorders Upstream Industry Analysis

      • 3.2.1 Upstream Industry Development Status

      • 3.2.2 Upstream Industry Development Forecast

      • 3.2.3 Impact of Upstream Industry on the Drugs for Metabolic Disorders Market

    • 3.3 Drugs for Metabolic Disorders Downstream Industry Analysis

      • 3.3.1 Downstream Industry Development Status

      • 3.3.2 Downstream Industry Development Forecast

      • 3.3.3 Impact of Downstream Industry on the Drugs for Metabolic Disorders Market

    Chapter 4 China Drugs for Metabolic Disorders Market, by Type

    • 4.1 China Drugs for Metabolic Disorders Market Trend, by Type

    • 4.2 Product Types of Major Suppliers

    • 4.3 Competitive Landscape of Major Types

    • 4.4 China Drugs for Metabolic Disorders Total Production Volume and Growth Rate from Production Side

    • 4.5 China Drugs for Metabolic Disorders Production Volume and Growth Rate, by Type

      • 4.5.1 China Drugs for Metabolic Disorders Production Volume and Growth Rate of Glycogen Metabolism Disease Drug

      • 4.5.2 China Drugs for Metabolic Disorders Production Volume and Growth Rate of Other

      • 4.5.3 China Drugs for Metabolic Disorders Production Volume and Growth Rate of Lipid Metabolism Disease Drug

      • 4.5.4 China Drugs for Metabolic Disorders Production Volume and Growth Rate of Amino Acid Metabolism Drug

    Chapter 5 China Drugs for Metabolic Disorders Market, by Application

    • 5.1 Downstream Market Overview

    • 5.2 Competitive Landscape of Major Applications

    • 5.3 Market Potential Analysis, by Application

    • 5.4 China Drugs for Metabolic Disorders Total Market Size and Growth Rate from Consumption End

    • 5.5 China Drugs for Metabolic Disorders Market Size and Growth Rate, by Application

      • 5.5.1 China Drugs for Metabolic Disorders Market Size and Growth Rate of Hospital

      • 5.5.2 China Drugs for Metabolic Disorders Market Size and Growth Rate of Paramary

    Chapter 6 China Drugs for Metabolic Disorders Market, by Region

    • 6.1 China Drugs for Metabolic Disorders Production Volume and Production Value, by Region

    • 6.2 China Drugs for Metabolic Disorders Sales Volume and Sales Value, by Region

    Chapter 7 North China Drugs for Metabolic Disorders Market Analysis

    • 7.1 North China Drugs for Metabolic Disorders Market, by Type

    • 7.2 North China Drugs for Metabolic Disorders Market, by Application

    Chapter 8 Central China Drugs for Metabolic Disorders Market Analysis

    • 8.1 Central China Drugs for Metabolic Disorders Market, by Type

    • 8.2 Central China Drugs for Metabolic Disorders Market, by Application

    Chapter 9 South China Drugs for Metabolic Disorders Market Analysis

    • 9.1 South China Drugs for Metabolic Disorders Market, by Type

    • 9.2 South China Drugs for Metabolic Disorders Market, by Application

    Chapter 10 East China Drugs for Metabolic Disorders Market Analysis

    • 10.1 East China Drugs for Metabolic Disorders Market, by Type

    • 10.2 East China Drugs for Metabolic Disorders Market, by Application

    Chapter 11 Northeast China Drugs for Metabolic Disorders Market Analysis

    • 11.1 Northeast China Drugs for Metabolic Disorders Market, by Type

    • 11.2 Northeast China Drugs for Metabolic Disorders Market, by Application

    Chapter 12 Southwest China Drugs for Metabolic Disorders Market Analysis

    • 12.1 Southwest China Drugs for Metabolic Disorders Market, by Type

    • 12.2 Southwest China Drugs for Metabolic Disorders Market, by Application

    Chapter 13 Northwest China Drugs for Metabolic Disorders Market Analysis

    • 13.1 Northwest China Drugs for Metabolic Disorders Market, by Type

    • 13.2 Northwest China Drugs for Metabolic Disorders Market, by Application

    Chapter 14 Company Profiles

      • 14.1 Beohrigher Ingelheim

        • 14.1.1 Beohrigher Ingelheim Company Profile

        • 14.1.2 Beohrigher Ingelheim Drugs for Metabolic Disorders Market Performance

        • 14.1.3 Product&Service Introduction

      • 14.2 Kythera

        • 14.2.1 Kythera Company Profile

        • 14.2.2 Kythera Drugs for Metabolic Disorders Market Performance

        • 14.2.3 Product&Service Introduction

      • 14.3 Metsubishi Tanabe Pharma

        • 14.3.1 Metsubishi Tanabe Pharma Company Profile

        • 14.3.2 Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Market Performance

        • 14.3.3 Product&Service Introduction

      • 14.4 Astra Zeneca

        • 14.4.1 Astra Zeneca Company Profile

        • 14.4.2 Astra Zeneca Drugs for Metabolic Disorders Market Performance

        • 14.4.3 Product&Service Introduction

      • 14.5 LG Life Science

        • 14.5.1 LG Life Science Company Profile

        • 14.5.2 LG Life Science Drugs for Metabolic Disorders Market Performance

        • 14.5.3 Product&Service Introduction

      • 14.6 Takeda Pharmaceutical

        • 14.6.1 Takeda Pharmaceutical Company Profile

        • 14.6.2 Takeda Pharmaceutical Drugs for Metabolic Disorders Market Performance

        • 14.6.3 Product&Service Introduction

      • 14.7 Novartis

        • 14.7.1 Novartis Company Profile

        • 14.7.2 Novartis Drugs for Metabolic Disorders Market Performance

        • 14.7.3 Product&Service Introduction

      • 14.8 KOWA

        • 14.8.1 KOWA Company Profile

        • 14.8.2 KOWA Drugs for Metabolic Disorders Market Performance

        • 14.8.3 Product&Service Introduction

      • 14.9 Fuji yakuhin

        • 14.9.1 Fuji yakuhin Company Profile

        • 14.9.2 Fuji yakuhin Drugs for Metabolic Disorders Market Performance

        • 14.9.3 Product&Service Introduction

    Chapter 15 Research Conclusions and Investment Suggestions

    • 15.1 Drugs for Metabolic Disorders Industry Research Conclusions

    • 15.2 Drugs for Metabolic Disorders Industry Investment Suggestions

      • 15.2.1 Suggestions on Industry Development Strategy

      • 15.2.2 Suggestions on Industry Investment Direction

      • 15.2.3 Suggestions on Industry Investment Strategy


    List of Tables and Figures

    • Figure China Drugs for Metabolic Disorders Industry Market Size (2018-2029)

    • Figure China Drugs for Metabolic Disorders Production Volume, Production Value and Growth Rate of Glycogen Metabolism Disease Drug (2018-2029)

    • Figure China Drugs for Metabolic Disorders Production Volume, Production Value and Growth Rate of Other (2018-2029)

    • Figure China Drugs for Metabolic Disorders Production Volume, Production Value and Growth Rate of Lipid Metabolism Disease Drug (2018-2029)

    • Figure China Drugs for Metabolic Disorders Production Volume, Production Value and Growth Rate of Amino Acid Metabolism Drug (2018-2029)

    • Figure China Drugs for Metabolic Disorders Sales Volume, Sales Value and Growth Rate of Hospital (2018-2029)

    • Figure China Drugs for Metabolic Disorders Sales Volume, Sales Value and Growth Rate of Paramary (2018-2029)

    • Figure North China Drugs for Metabolic Disorders Market Size and Growth Rate from 2018-2029

    • Figure Central China Drugs for Metabolic Disorders Market Size and Growth Rate from 2018-2029

    • Figure South China Drugs for Metabolic Disorders Market Size and Growth Rate from 2018-2029

    • Figure East China Drugs for Metabolic Disorders Market Size and Growth Rate from 2018-2029

    • Figure Northeast China Drugs for Metabolic Disorders Market Size and Growth Rate from 2018-2029

    • Figure Southwest China Drugs for Metabolic Disorders Market Size and Growth Rate from 2018-2029

    • Figure Northwest China Drugs for Metabolic Disorders Market Size and Growth Rate from 2018-2029

    • Figure Drugs for Metabolic Disorders Industry Chain

    • Table Product Types of Major Suppliers in 2023

    • Figure China Drugs for Metabolic Disorders Market Share by Type in 2018

    • Figure China Drugs for Metabolic Disorders Market Share by Type in 2023

    • Figure China Drugs for Metabolic Disorders Total Production Volume and Growth Rate from Production Side (2018-2023)

    • Figure China Drugs for Metabolic Disorders Production Volume and Growth Rate of Glycogen Metabolism Disease Drug (2018-2023)

    • Figure China Drugs for Metabolic Disorders Production Volume and Growth Rate of Other (2018-2023)

    • Figure China Drugs for Metabolic Disorders Production Volume and Growth Rate of Lipid Metabolism Disease Drug (2018-2023)

    • Figure China Drugs for Metabolic Disorders Production Volume and Growth Rate of Amino Acid Metabolism Drug (2018-2023)

    • Figure China Drugs for Metabolic Disorders Market Share by Application in 2018

    • Figure China Drugs for Metabolic Disorders Market Share by Application in 2023

    • Figure China Drugs for Metabolic Disorders Total Market Size and Growth Rate from Consumption End

    • Figure China Drugs for Metabolic Disorders Market Size and Growth Rate of Hospital (2018-2023)

    • Figure China Drugs for Metabolic Disorders Market Size and Growth Rate of Paramary (2018-2023)

    • Table China Drugs for Metabolic Disorders Production Volume by Region (2018-2023)

    • Table China Drugs for Metabolic Disorders Production Volume Share by Region (2018-2023)

    • Figure China Drugs for Metabolic Disorders Production Volume Share by Region (2018-2023)

    • Table China Drugs for Metabolic Disorders Production Value by Region (2018-2023)

    • Table China Drugs for Metabolic Disorders Production Value Share by Region (2018-2023)

    • Figure China Drugs for Metabolic Disorders Production Value Share by Region (2018-2023)

    • Table China Drugs for Metabolic Disorders Sales Volume by Region (2018-2023)

    • Table China Drugs for Metabolic Disorders Sales Volume Share by Region (2018-2023)

    • Figure China Drugs for Metabolic Disorders Sales Volume Share by Region (2018-2023)

    • Table China Drugs for Metabolic Disorders Sales Value by Region (2018-2023)

    • Table China Drugs for Metabolic Disorders Sales Value Share by Region (2018-2023)

    • Figure China Drugs for Metabolic Disorders Sales Value Share by Region (2018-2023)

    • Table North China Drugs for Metabolic Disorders Production Volume by Type (2018-2023)

    • Table North China Drugs for Metabolic Disorders Production Volume Share by Type (2018-2023)

    • Figure North China Drugs for Metabolic Disorders Production Volume Share by Type (2018-2023)

    • Table North China Drugs for Metabolic Disorders Sales Volume by Application (2018-2023)

    • Table North China Drugs for Metabolic Disorders Sales Volume Share by Application (2018-2023)

    • Figure North China Drugs for Metabolic Disorders Sales Volume Share by Application (2018-2023)

    • Table Central China Drugs for Metabolic Disorders Production Volume by Type (2018-2023)

    • Table Central China Drugs for Metabolic Disorders Production Volume Share by Type (2018-2023)

    • Figure Central China Drugs for Metabolic Disorders Production Volume Share by Type (2018-2023)

    • Table Central China Drugs for Metabolic Disorders Sales Volume by Application (2018-2023)

    • Table Central China Drugs for Metabolic Disorders Sales Volume Share by Application (2018-2023)

    • Figure Central China Drugs for Metabolic Disorders Sales Volume Share by Application (2018-2023)

    • Table South China Drugs for Metabolic Disorders Production Volume by Type (2018-2023)

    • Table South China Drugs for Metabolic Disorders Production Volume Share by Type (2018-2023)

    • Figure South China Drugs for Metabolic Disorders Production Volume Share by Type (2018-2023)

    • Table South China Drugs for Metabolic Disorders Sales Volume by Application (2018-2023)

    • Table South China Drugs for Metabolic Disorders Sales Volume Share by Application (2018-2023)

    • Figure South China Drugs for Metabolic Disorders Sales Volume Share by Application (2018-2023)

    • Table East China Drugs for Metabolic Disorders Production Volume by Type (2018-2023)

    • Table East China Drugs for Metabolic Disorders Production Volume Share by Type (2018-2023)

    • Figure East China Drugs for Metabolic Disorders Production Volume Share by Type (2018-2023)

    • Table East China Drugs for Metabolic Disorders Sales Volume by Application (2018-2023)

    • Table East China Drugs for Metabolic Disorders Sales Volume Share by Application (2018-2023)

    • Figure East China Drugs for Metabolic Disorders Sales Volume Share by Application (2018-2023)

    • Table Northeast China Drugs for Metabolic Disorders Production Volume by Type (2018-2023)

    • Table Northeast China Drugs for Metabolic Disorders Production Volume Share by Type (2018-2023)

    • Figure Northeast China Drugs for Metabolic Disorders Production Volume Share by Type (2018-2023)

    • Table Northeast China Drugs for Metabolic Disorders Sales Volume by Application (2018-2023)

    • Table Northeast China Drugs for Metabolic Disorders Sales Volume Share by Application (2018-2023)

    • Figure Northeast China Drugs for Metabolic Disorders Sales Volume Share by Application (2018-2023)

    • Table Southwest China Drugs for Metabolic Disorders Production Volume by Type (2018-2023)

    • Table Southwest China Drugs for Metabolic Disorders Production Volume Share by Type (2018-2023)

    • Figure Southwest China Drugs for Metabolic Disorders Production Volume Share by Type (2018-2023)

    • Table Southwest China Drugs for Metabolic Disorders Sales Volume by Application (2018-2023)

    • Table Southwest China Drugs for Metabolic Disorders Sales Volume Share by Application (2018-2023)

    • Figure Southwest China Drugs for Metabolic Disorders Sales Volume Share by Application (2018-2023)

    • Table Northwest China Drugs for Metabolic Disorders Production Volume by Type (2018-2023)

    • Table Northwest China Drugs for Metabolic Disorders Production Volume Share by Type (2018-2023)

    • Figure Northwest China Drugs for Metabolic Disorders Production Volume Share by Type (2018-2023)

    • Table Northwest China Drugs for Metabolic Disorders Sales Volume by Application (2018-2023)

    • Table Northwest China Drugs for Metabolic Disorders Sales Volume Share by Application (2018-2023)

    • Figure Northwest China Drugs for Metabolic Disorders Sales Volume Share by Application (2018-2023)

    • Table Beohrigher Ingelheim Company Profile

    • Table Beohrigher Ingelheim Drugs for Metabolic Disorders Revenue, Price and Gross (2018-2023)

    • Table Kythera Company Profile

    • Table Kythera Drugs for Metabolic Disorders Revenue, Price and Gross (2018-2023)

    • Table Metsubishi Tanabe Pharma Company Profile

    • Table Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Revenue, Price and Gross (2018-2023)

    • Table Astra Zeneca Company Profile

    • Table Astra Zeneca Drugs for Metabolic Disorders Revenue, Price and Gross (2018-2023)

    • Table LG Life Science Company Profile

    • Table LG Life Science Drugs for Metabolic Disorders Revenue, Price and Gross (2018-2023)

    • Table Takeda Pharmaceutical Company Profile

    • Table Takeda Pharmaceutical Drugs for Metabolic Disorders Revenue, Price and Gross (2018-2023)

    • Table Novartis Company Profile

    • Table Novartis Drugs for Metabolic Disorders Revenue, Price and Gross (2018-2023)

    • Table KOWA Company Profile

    • Table KOWA Drugs for Metabolic Disorders Revenue, Price and Gross (2018-2023)

    • Table Fuji yakuhin Company Profile

    • Table Fuji yakuhin Drugs for Metabolic Disorders Revenue, Price and Gross (2018-2023)


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US